SUFENTANYL
Vaso-occlusive Crisis
Assistance Publique - Hôpitaux de ParisSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Vaso-occlusive Crisis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VEPOLOXAMER Mast Therapeutics, Inc. | Phase 3 | BB |
Rivipansel GlycoMimetics Incorporated | Phase 3 | B |
VITAMIN D Beni-Suef University | Phase 2/3 | B |
ZINC SULFATE Beni-Suef University | Phase 2/3 | B |
SIMVASTATIN Beni-Suef University | Phase 2/3 | B |
View all 18 →
Same molecule, other indications
SUFENTANYL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →